Evidence map›Paper›PMID 32944737›Full record

ArticleDiseases of the esophagus : official journal of the International Society for Diseases of the Esophagus2021

The SpaTemp cohort: 168 nondysplastic Barrett's esophagus surveillance patients with and without progression to early neoplasia to evaluate the distribution of biomarkers over space and time.

N F Frei, K Konté, L C Duits, E Klaver, F J Ten Kate, G J Offerhaus, S L Meijer, M Visser, C A Seldenrijk, E J Schoon and 5 more

Open access · greenAbstract read
In one paragraph

Article in Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 1 country.

N F FreiDepartment of Gastroenterology and Hepatology, Amsterdam UMC, location Vrije Universiteit, Amsterdam, The Netherlands.
K KontéDepartment of Gastroenterology and Hepatology, Amsterdam UMC, location Vrije Universiteit, Amsterdam, The Netherlands.
L C DuitsDepartment of Gastroenterology and Hepatology, Amsterdam UMC, location Vrije Universiteit, Amsterdam, The Netherlands.
E KlaverDepartment of Gastroenterology and Hepatology, Amsterdam UMC, location Vrije Universiteit, Amsterdam, The Netherlands.
F J Ten KateDepartment of Pathology, University Medical Center, Utrecht, The Netherlands.
G J OfferhausDepartment of Pathology, University Medical Center, Utrecht, The Netherlands.
S L MeijerDepartment of Pathology, Amsterdam UMC, location Academic Medical Center, Amsterdam, The Netherlands.
M VisserDepartment of Pathology, Symbiant BV, Zaans Medical Center, Zaandam, The Netherlands.
C A SeldenrijkDepartment of Pathology, Pathology-DNA BV, St. Antonius Hospital, Nieuwegein, The Netherlands.
E J SchoonDepartment of Gastroenterology and Hepatology, Catharina Hospital, Eindhoven, The Netherlands.
B L A M WeustenDepartment of Gastroenterology and Hepatology, St. Antonius Hospital, Nieuwegein, The Netherlands.
B E SchenkDepartment of Gastroenterology and Hepatology, Isala Klinieken, Zwolle, The Netherlands.
R C Mallant-HentDepartment of Gastroenterology, Flevo Hospital, Almere, the Netherlands.
J J BergmanDepartment of Gastroenterology and Hepatology, Amsterdam UMC, location Vrije Universiteit, Amsterdam, The Netherlands.
R E PouwDepartment of Gastroenterology and Hepatology, Amsterdam UMC, location Vrije Universiteit, Amsterdam, The Netherlands.
Amsterdam University Medical Centers · NLSt. Antonius Ziekenhuis · NLUniversity Medical Center Utrecht · NLVrije Universiteit Amsterdam · NLIsala · NLRadboud University Nijmegen · NLZaans Medisch Centrum · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The ReBus cohort is a matched nested case-control cohort of patients with nondysplastic (ND) Barrett's esophagus (BE) at baseline who progressed (progressors) or did not progress (nonprogressors) to high-grade dysplasia (HGD) or cancer. This cohort is constructed using the most stringent inclusion criteria to optimize explorative studies on biomarkers predicting malignant progression in NDBE. These explorative studies may benefit from expanding the number of cases and by incorporating samples that allow assessment of the biomarker over space (spatial variability) and over time (temporal variability). To (i) update the ReBus cohort by identifying new progressors and (ii) identify progressors and nonprogressors within the updated ReBus cohort containing spatial and temporal information. The ReBus cohort was updated by identifying Barrett's patients referred for endoscopic work-up of neoplasia at 4 tertiary referral centers. Progressors and nonprogressors with a multilevel (spatial) endoscopy and additional prior (temporal) endoscopies were identified to evaluate biomarkers over space and over time. The original ReBus cohort consisted of 165 progressors and 723 nonprogressors. We identified 65 new progressors meeting the same strict selection criteria, resulting in a total number of 230 progressors and 723 matched nonprogressors in the updated ReBus cohort. Within the updated cohort, 61 progressors and 107 nonprogressors (mean age 61 ± 10 years) with a spatial endoscopy (median level 3 [2-4]) were identified. 33/61 progressors and 50/107 nonprogressors had a median of 3 (2-4) additional temporal endoscopies. Our updated ReBus cohort consists of 230 progressors and 723 matched nonprogressors using the most strict selection criteria. In a subgroup of 168 Barrett's patients (the SpaTemp cohort), multiple levels have been sampled at baseline and during follow-up providing a unique platform to study spatial and temporal distribution of biomarkers in BE.

Indexed as

AdenocarcinomaBarrett EsophagusEsophageal NeoplasmsBiomarkersDisease ProgressionHumansInfant, NewbornBiomarkersBarrett’s EsophagusBiomarkerEsophageal AdenocarcinomaRisk StratificationSpatialTemporal

Identifiers

PMID32944737
PMCPMC9155949
OpenAlexW3087678009

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.